Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,

Shares of Eli Lilly & Co. LLY sank 0.30% to $797.48 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,836.22 and the Dow Jones Industrial Average DJIA rising 0.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 503.77% and currently trading at $798.25. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with its dominant GLP-1 drug, Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity.